Please find below relevant investor relations documents.
We place a high value on maintaining strong relationships with our stakeholder community, ensuring a consistent level of information. The following analysts cover the Pharma Equity Group share:
Danske Bank
Thomas Bowers
Senior Equity Analyst, Healthcare
Investment Banking & Securities
Holmens Kanal 2-12, DK-1092 Copenhagen K
Direct +45 45 14 14 93 | Mob +45 41 95 01 32
thbo@danskebank.com | www.danskebank.com
Analyst Group, Sweden
Oscar Mårdh
Share Analyst
Cell. +46 76 044 29 70
E-mail. oscar.mardh@analystgroup.se
AG Equity Research AB
Riddargatan 12B
114 35 Stockholm
HC Andersen Capital, Denmark
Claus Thestrup, Stock Analytics
Cell: +46 707 553 057
E-mail. claus@hcandersencapital.dk
HC Andersen Capital A/S
Bredgade 23B, 2. Sal1260 Københa
To Pharma Equity Group, openness and transparency are essential in maintaining good relations with investors. The company aims to give the market open, satisfactory information about the company’s operations, strategy and results with a view to ensuring fair pricing of the share and to contribute to ensuring good corporate governance.
All stakeholders should have fast, equal access to important information about the company’s development and growth. One of the ways this is effectuated is by publicizing in-house knowledge in company announcements to Nasdaq Copenhagen, which are subsequently made available at the company’s website, www.pharmaequitygroup.com.
Investors and other interested parties can sign up for notification of published company announcements, newsletters and other material in the investor section of the website. Other publicized information, including general corporate and investor presentations, are made available to the general public on the website.
To ensure an efficient, expedient dialog with our shareholders, the company encourages its shareholders to let their shareholding be registered and to participate in Annual General Meetings. Investor Relations is also responsible for ensuring that information from the company’s IR stakeholders is passed on to the Management and the Board of Directors of the Company.
Thomas Kaas Selsø, CEO
Thomas.kaas.selsoe@pharmaequitygroup.com
Pharma Equity Group A/S
Slotsmarken 18, 2.th.
DK-2970 Hørsholm
Denmark
CVR 26791413
For general enquiries contact us at info@pharmaequitygroup.com
For Investor related enquiries contact us at investor@
For any drug quality issues, complaints or adverse events,
contact us at quality@reponex.dk
All rights reserved, 2024